Last $49.58 USD
Change Today -0.10 / -0.20%
Volume 73.3K
RDY On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 5:15 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

doctor reddy's lab-adr (RDY) Key Developments

Dr. Reddy’s Laboratories Launches Valganciclovir Tablets USP 450 mg

Dr. Reddy’s Laboratories announced that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE® (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.

Dr. Reddy's Laboratories Ltd. Launches Docetaxel Injection USP

Dr. Reddy's Laboratories announced that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE(R) (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA). Dr. Reddy's Docetaxel Injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does NOT require a prior dilution with a diluent and is ready to add to the Intravenous Infusion solution.

Dr. Reddy’s Laboratories Launches its Over-The-Counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets

Dr. Reddy’s Laboratories announced that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg /120 mg, a bioequivalent generic version of Allegra-D® 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA). The Allegra-D® 12 Hour brand has U.S. sales of approximately $49.8 million for the latest 52 weeks ending October 6, 2014 for Total US Multi Outlet according to IRI. Dr. Reddy’s Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg /120 mg is available in a 20 count blister.

Dr. Reddy's Laboratories Ltd. Presents at HSBC 6th Annual Asia Investor Forum-New York, Nov-18-2014

Dr. Reddy's Laboratories Ltd. Presents at HSBC 6th Annual Asia Investor Forum-New York, Nov-18-2014 . Venue: The Westin, New York Grand Central, New York, New York, United States.

Dr. Reddy's Laboratories Ltd. Reports Unaudited Consolidated Cash Flow Results for the Six Months Ended September 30, 2014

Dr. Reddy's Laboratories Ltd. reported unaudited consolidated cash flow results for the six months ended September 30, 2014. For the quarter, the company reported net cash from operating activities of INR 9,013 million against INR 5,325 million a year ago. Expenditure on property, plant and equipment was INR 4,235 million against INR 5,611 million a year ago. Expenditure on other intangible assets was INR 353 million against INR 287 million a year ago. Purchase of other investments was INR 16,360 million against INR 10,576 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDY:US $49.58 USD -0.10

RDY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 1,092 INR +2.10
Cipla Ltd/India 625.10 INR -5.00
Croda International PLC 2,596 GBp -34.00
Endo International PLC $72.10 USD +0.34
Symrise AG €50.26 EUR -0.331
View Industry Companies
 

Industry Analysis

RDY

Industry Average

Valuation RDY Industry Range
Price/Earnings 24.0x
Price/Sales 3.8x
Price/Book 5.4x
Price/Cash Flow 23.9x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DOCTOR REDDY'S LAB-ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.